Visby Medical
Plug and Play VenturesTokyo, US · Founded 2012 · 177 employees on LinkedIn · 9 known investors
Visby Medical manufactures at-home PCR tests for sexually transmitted infections, providing FDA-authorized results in 30 minutes. The company serves individuals seeking fast, private STI testing without clinical delays, with integrated telehealth access for positive results.
Also known as Visby
Founders & leadership
Visby Medical was founded in 2012 by Adam de la Zerda.
Investors · 9
Company profile
researched Aug 2026Visby Medical develops and sells a palm-sized, single-use PCR testing device for at-home sexual health screening. The product tests for three curable sexually transmitted infections — chlamydia, gonorrhea and trichomoniasis — and returns results in approximately 30 minutes without any sample mailing or laboratory turnaround. The company states the test delivers 98% accuracy and describes it as offering PCR performance comparable to laboratory testing.
The test kit is shipped directly to users in discreet packaging and includes visual, step-by-step instructions and short instructional videos. Results are delivered through a password-protected mobile app rather than displayed on the physical device, a design the company frames around user privacy. Users who test positive are connected to a same-day telehealth consultation with a third-party licensed provider, who may prescribe treatment at their discretion; medication cost is not included with the kit. Supporting resources include FAQs, user instructions and customer support.
Business model
Visby Medical sells at-home diagnostic test kits directly to consumers, shipping the device to the user's address. Telehealth consultation with a third-party licensed provider is bundled with a positive result, while the cost of any prescribed medication is excluded and borne by the user.
Revenue is generated from direct sales of at-home test kits to consumers, with promotional discounting used on the company's site (for example, a limited-time $30 discount).
▸Full profile — market position, technology, go-to-market, risks & controversies
Market position
Visby Medical states that the FDA authorized its product as the first at-home test for chlamydia, gonorrhea and trichomoniasis, the three most common curable STIs as identified by the Centers for Disease Control and Prevention.
The company positions its device against mail-in laboratory testing and clinic visits by combining PCR-level accuracy with a 30-minute on-site result, FDA authorization, discreet delivery, app-based private result reporting, and an included same-day telehealth pathway to treatment for positive results.
Technology
A single-use, handheld device that performs polymerase chain reaction (PCR) amplification at the point of use, described by the company as making laboratory-grade PCR possible at home. Results are reported in about 30 minutes through a companion password-protected app that also delivers muted, segmented video instructions.
Go-to-market
Direct-to-consumer online ordering via the company's website, supported by promotional discounts, customer reviews and testimonials, social media presence, and referenced partner relationships.
Individuals seeking private sexual health screening outside a clinical setting, including asymptomatic people; the company notes that most women and many men experience no symptoms from these infections.
Risks & controversies
Treatment decisions rest with third-party licensed providers rather than the company, and medication costs are not covered by the kit purchase. The panel is limited to three infections, and the company reports 98% accuracy rather than perfect concordance; user feedback referenced on the site includes at least one report of a delay in receiving results.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 5
by search overlap
Companies competing with Visby Medical for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 2
launches, deals, and filingsVisby Medical introduced a direct-to-consumer at-home PCR test kit returning results in 30 minutes, with app-based results and included same-day telehealth for positive results.
The company reports that the FDA authorized its product as the first at-home test for chlamydia, gonorrhea and trichomoniasis.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- Visby Medicalvisbymedical.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Visby Medical do?
- Visby Medical sells an FDA-authorized at-home PCR test that returns chlamydia, gonorrhea and trichomoniasis results in 30 minutes.
- Who founded Visby Medical?
- Visby Medical was founded by Adam de la Zerda in 2012.
- Who are Visby Medical's investors?
- Visby Medical's investors include +ND Capital, 1809 Capital, Amplify Partners, Artiman Ventures, G Vision Capital, Seraph Group, Valo Ventures, J-Ventures and 1 more.
- Where is Visby Medical headquartered?
- Visby Medical is headquartered in Tokyo, US.